Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Ulivi, Paola ^a   Mercatali, Laura ^a   Casoni, Gian Luca ^b   Scarpi, Emanuela ^a   Bucchi, Lauro ^a   Silvestrini, Rosella ^a   Sanna, Stefano ^b   Monteverde, Marco ^b   Amadori, Dino ^a   Poletti, Venerino ^b   Zoli, Wainer ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HAPTOGLOBIN; MESSENGER RNA; PRO PLATELET BASIC PROTEIN; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE DEIMINASE 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA DETERMINATION; FEMALE; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84874463234     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057401     Document Type: Article

References (34)

1. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, et al. (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2: 593-602.
2. Saito Y, Nagamoto N, Ota S, Sato M, Sagawa M, et al. (1992) Results of surgical treatment for roentgenographically occult bronchogenic squamous cell carcinoma. J Thorac Cardiovasc Surg 104: 401-407.
3. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, et al (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409.
4. Berrington de González A, Kim KP, Berg CD, (2008) Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. J Med Screen 15: 153-158.
5. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, et al. (2005) CT screening for lung cancer: five-year prospective experience. Radiology 235: 259-265.
6. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, et al. (2001) Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 61: 4675-4678.
7. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, et al. (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21: 3902-3908.
8. Ulivi P, Mercatali L, Zoli W, Dell'amore D, Poletti V, et al. (2008) Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. Thorax 63: 843-844.
9. Zhang R, Shao F, Wu X, Ying K, (2010) Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 69: 225-231.
10. Ulivi P, Zoli W, Calistri D, Fabbri F, Tesei A, et al. (2006) p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol 206: 611-615.
11. Sung HJ, Cho JY, (2008) Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41: 615-625.
12. Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, et al. (2005) Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11: 1219-1225.
13. Belinsky S, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, et al. (2005) Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11: 6505-6511.
14. Andriani F, Conte D, Mastrangelo T, Leon M, Ratcliffe C, et al. (2004) Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer 108: 91-96.
15. Kneip C, Schmidt B, Seegebarth A, Weickmann S, Fleischhacker M, et al. (2011) SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 6: 1632-1638.
16. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, et al. (2011) Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 4: 575-586.
17. Zander T, Hofmann A, Staratschek-Jox A, Classen S, Debey-Pascher S, et al. (2011) Blood-based gene expression signatures in non-small cell lung cancer. Clin Cancer Res 17: 3360-3367.
18. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, et al. (2006) Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42: 768-778.
19. Abdullah M, Schultz H, Kähler D, Branscheid D, Dalhoff K, et al. (2009) Expression of the acute phase protein haptoglobin in human lung cancer and tumor-free lung tissues. Pathol Res Pract 205: 639-647.
20. Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, et al. (2009) Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol 27: 2787-2792.
21. Cuthbert GL, Daujat S, Snowden AW, Erdjument-Bromage H, Hagiwara T, et al. (2004) Histone deimination antagonizes arginine methylation. Cell 118: 545-553.
22. Chang X, Han J, Pang L, Zhao Y, Yang Y, et al. (2009) Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 9: 40.
23. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, et al. (2004) Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22: 4157-4164.
24. Armitage P, Berry G (1987) Statistical methods in medical research, 2nd edition. Boston: Blackwell Scientific Publications p. 387-93.
25. McWilliams A, Lam S, (2005) Lung cancer screening. Curr Opin Pulm Med 11: 272-277.
26. Wardwell NR, Massion PP, (2005) Novel strategies for the early detection and prevention of lung cancer. Semin Oncol 32: 259-268.
27. Sozzi G, Roz L, Conte D, Mariani L, Andriani F, et al. (2009) Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med 179: 69-74.
28. Xie GS, Hou AR, Li LY, Gao YN, Cheng SJ, (2004) Quantification of plasma DNA as a screening tool for lung cancer. Chin Med J (Engl) 117: 1485-1488.
29. Yoon KA, Park S, Lee SH, Kim JH, Lee JS, (2009) Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. Mol Diagn 11: 182-185.
30. Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, et al. (2009) Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 64: 92-97.
31. Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, et al. (2005) Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 51: 113-118.
32. Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, et al. (2008) Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol 3: 365-373.
33. Schmidt B, Weickmann S, Witt C, Fleischhacker M, (2008) Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease Ann N Y Acad Sci. 1137: 207-213.
34. Casoni GL, Ulivi P, Mercatali L, Chilosi M, Tomassetti S, et al. (2010) Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. Int J Biol Markers 25: 229-235.